Bristol-Myers Squibb Company
page
1
of
1
FDA studying possible cancer risk of anti-diabetes drugs
Mar 15, 2013 10:09 EDT
The US Food and Drug Administration said Thursday it was reviewing results of unpublished studies hinting at higher risks of ulcers and pancreatic cancer for users of certain anti-diabetes drugs.
US stocks edge up on fresh hopes for 'cliff' deal
Dec 31, 2012 11:24 EST
US stocks traded higher in early action on the last day of the year Monday as investors held out hope for a last-minute deal hours before the deadline to avoid the economy-crunching fiscal cliff.
Top CEOs unite to oppose HIV travel restrictions
Jul 22, 2012 09:37 EDT
Chief executives of more than 20 multinational corporations called Sunday on 46 countries to lift restrictions on travellers who are HIV positive.
Immune boosters show promise against cancer: study
Jun 02, 2012 02:18 EDT
A pair of experimental treatments that fight cancer by boosting the immune system have shown promise in early studies and deserve testing in larger patient groups, said US research released Saturday.
US recalls organ storage fluid over contamination fears
Mar 29, 2012 17:15 EDT
A major US pharmaceutical company on Thursday issued a wide-spanning global recall of the fluid used to store organs for potential transplants over fears it could be contaminated.
FDA extends review of Alexza product, shares fall
Jan 23, 2012 09:28 EST
(Reuters) - Alexza Pharmaceuticals Inc said U.S. health regulators extended the review date for its novel anti-psychotic treatment by three months after the company amended its approval application, sending its shares down as much as 19 percent.
U.S. rebuffs AstraZeneca, Bristol on diabetes drug
Jan 19, 2012 04:23 EST
LONDON (Reuters) - U.S. drug regulators need further clinical data, possibly including new clinical studies, before approving a new diabetes drug from AstraZeneca and Bristol-Myers Squibb.
Novartis cuts 2,000 US jobs after patent loss
Jan 13, 2012 08:37 EST
Swiss pharmaceutical company Novartis has again drastically reduced its workforce in the United States to deal with the expiry of an important patent and its failure to get traction on other drugs, the firm said on Friday.
Alexza to explore strategic options
Dec 16, 2011 21:04 EST
(Reuters) - Alexza Pharmaceuticals Inc said it will explore options including sale of assets, strategic business combination, or partnerships.
Stock index futures lower, results eyed
Dec 16, 2011 10:42 EST
(Reuters) - Stock index futures pointed to a lower open on Wall Street on Thursday, with futures for the S&P 500, Dow Jones and Nasdaq 100 down 0.03 to 0.2 percent at 1004 GMT.
Roche melanoma drug wins European green light
Dec 16, 2011 08:21 EST
LONDON (Reuters) - European regulators have recommended approval of a targeted melanoma drug from Swiss group Roche Holding AG, opening the way to a new treatment option for patients with the deadliest form of skin cancer.
Ariad leukemia drug helps 47 percent of patient: study
Dec 11, 2011 19:31 EST
SAN DIEGO (Reuters) - Early results from a pivotal trial of Ariad Pharmaceuticals Inc's experimental leukemia drug ponatinib show it is effective in nearly half of patients who had stopped responding to currently available drugs.
FDA staff worried about lung risk with Alexza drug
Dec 08, 2011 13:32 EST
WASHINGTON (Reuters) - Alexza Pharmaceutical's experimental drug for calming down patients with schizophrenia or bipolar disorder can cause severe lung problems, U.S. Food and Drug Administration reviewers said.
FDA staff worried about lung risk with Alexza drug
Dec 08, 2011 13:31 EST
WASHINGTON (Reuters) - Alexza Pharmaceutical's experimental drug for calming down patients with schizophrenia or bipolar disorder can cause severe lung problems, U.S. Food and Drug Administration reviewers said.
Spending on depression up, quality of care lagging
Dec 06, 2011 17:27 EST
NEW YORK (Reuters Health) - Spending on depression has gone up by nearly a third with no clear improvement in the quality of care, according to Medicaid claims data from Florida.
Bristol-Myers, J&J team up against hepatitis C
Dec 02, 2011 13:11 EST
NEW YORK (Reuters) - Bristol-Myers Squibb Co and Johnson & Johnson plan to jointly develop experimental treatments for hepatitis C in a market worth billions of dollars.
Obama raises U.S. goal on fighting AIDS
Dec 01, 2011 15:55 EST
WASHINGTON (Reuters) - President Barack Obama vowed to boost U.S. efforts to fight AIDS with a new target of providing treatment to 6 million people worldwide by 2013, up from an earlier goal of 4 million.
Bristol/Pfizer anti-clot drug gets fast FDA review
Nov 29, 2011 15:35 EST
(Reuters) - A promising new drug shown to be better than warfarin at preventing strokes in patients with a dangerously irregular heartbeat may reach the U.S. market more quickly after health regulators gave it an expedited review.
Gilead bets $11 billion on hepatitis in Pharmasset deal
Nov 21, 2011 17:02 EST
(Reuters) - Gilead Sciences Inc <GILD.O> struck a deal to buy biotechnology company Pharmasset Inc <VRUS.O> for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.
Gilead bets $11 billion on hepatitis in Pharmasset deal
Nov 21, 2011 16:28 EST
(Reuters) - Gilead Sciences Inc <GILD.O> struck a deal to buy biotechnology company Pharmasset Inc <VRUS.O> for about $11 billion in a huge and risky bet on the next generation of hepatitis C treatments.
Facts from the Wikipedia page:
 | |
| Type | Public |
|---|---|
| Founded | 1887 |
| Headquarters | New York, New York |
| Key people | James Cornelius, CEO |
| Industry | Pharmaceuticals |
| Revenue | ▲ US$ 19.98 billion (2008) |
| Net income | ▲ US$ 2.165 billion (2008) |
| Employees | 35,000 (2009) |
| Website | www.bms.com |
